BiotechTV

Daily biotech news, content, and exclusive interviews.

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2.

Full video: https://t.co/TEZUHYx6c0

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐏𝐡𝐢𝐥𝐚𝐝𝐞𝐥𝐩𝐡𝐢𝐚: Earlier this month, @Agilent agreed to acquire Philadelphia based @Proscia, a provider of digital pathology software for clinical and life-sciences customers, for $240M up front and up to $30M more.

Full video: https://t.co/2B3ZyQsdRW

[BiotechTV @BiotechTV]

𝐖𝐞𝐞𝐤 𝐢𝐧 𝐑𝐞𝐯𝐢𝐞𝐰: Biotech had a small bounce this week, though clinical trial news mostly leaned towards the negative side.

$XBI $EYPT $AARD $IRON $GSK $MRNA $TNGX $EVAX

[BiotechTV @BiotechTV]

@tranbryannguyen @Mizuho @salimqsyed 💯

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @Mizuho Senior Biotech Analyst @salimqsyed shares his take on biotech's current lull, and discusses companies he covers.

$XBI $RCUS $CYTK $BBIO $MAZE $IPSC

Full video: https://t.co/P1LateCa0Z

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @Immuneering Co-Founder & CEO @BenZeskind discusses the future of the third generation MEK inhibitor atebimetinib, which has shown promising data in first line pancreatic cancer. $IMRX

Full video: https://t.co/9YdLBmSYWA

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @BarclaysCIB Biotech Analyst Ellie Merle previews this weekend's highly anticipated cancer vaccine data from Merck and Moderna at ESMO. She sees scenarios for the stock ranging from $100 to mid $400's. $MRK $MRNA

Full video: https://t.co/5Jia8niCFk

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Lexeo Therapeutics' CEO Nolan Townsend discusses a recent acquisition in Friedreich's ataxia and upcoming data in PKP2 arrhythmogenic cardiomyopathy. $LXEO

Full video: https://t.co/1kShbDgirT

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: BiotechTV will be at the iconic @NYSE today. Watch for these interviews this afternoon. $LXEO $IMRX

[BiotechTV @BiotechTV]

𝐂𝐨𝐧𝐠𝐫𝐚𝐭𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 𝐎𝐫𝐜𝐡𝐞𝐬𝐭𝐫𝐚: Congratulations to our sponsor and partner Orchestra - it was announced moments ago that they are being acquired by @OpenAI. Kudos to @ashokaraj_ and the entire Orchestra team!

[Brad Loncar @bradloncar]

I’m very happy for @ashokaraj_ and the Orchestra team. It has been an honor working with them this year as a sponsor partner to @BiotechTV, and learning from the best how AI and agents are transforming biopharma. Very smart move by @OpenAI!

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Penn spin-out Incuta Therapeutics is developing a long-lasting JAK inhibitor for hidradenitis suppurativa that is designed to concentrate at the site of the lesions.

Full video: https://t.co/1fUMXJYWZG

[BiotechTV @BiotechTV]

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝: Biotech company chair, director, and former CEO Paula Soteropoulos discusses learnings from her career and announces a new book she and her daughter wrote about women's health.

Watch the full discussion: https://t.co/4sj0Q6Wqvj

[BiotechTV @BiotechTV]

𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: Episode 50 | @ThirdRockV's Bob Tepper describes working in biotech (Cell Genesys & Millennium) in the early days of the sector, and Third Rock's unique culture.

Watch the full episode: https://t.co/Lqft2MaunK

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: London based IMU Biosciences announced today that it will use its immune system profiling platform with 80,000 blood samples from UK Biobank to create a large-scale picture of the human immune system.

Full video: https://t.co/O8JLbBMoiY

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Nouscom announced a $135M series D raise this morning. It will help the company advance through a registration study its cancer vaccine that is meant to prevent the occurrence of Lynch Syndrome in genetic carriers.

[BiotechTV @BiotechTV]

𝐖𝐞𝐞𝐤 𝐢𝐧 𝐑𝐞𝐯𝐢𝐞𝐰: XBI was down over 6% this week.

$GUTS $CTNM $VTRS $IBRX $BNTX $ABBV

[BiotechTV @BiotechTV]

𝐍𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐲 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐃𝐚𝐲: @NrgTherapeutics recently announced the target of its lead ALS program, NLRX1. Co-Founder and CEO Neil Miller describes it and discusses neurology drug development.

[BiotechTV @BiotechTV]

𝐀𝐥𝐢𝐠𝐧 𝐒𝐮𝐦𝐦𝐢𝐭 𝟐𝟎𝟐𝟔: @generaloncology was born from a family's effort to come up with something new for a woman with pancreatic cancer.

Full video: https://t.co/qnsiaOydqi

[BiotechTV @BiotechTV]

𝐀𝐥𝐢𝐠𝐧 𝐒𝐮𝐦𝐦𝐢𝐭 𝟐𝟎𝟐𝟔: @ReleviumMed is developing what it believes is the first TRPV1 agonist that mitigates the burning tolerability issue seen with others in the past.

Full video: https://t.co/IXWRQ3VFtb